KEGG   DRUG: Polatuzumab vedotin
Entry
D10761                      Drug                                   

Name
Polatuzumab vedotin (USAN);
Polatuzumab vedotin (genetical recombination) (JAN);
Polatuzumab vedotin-piiq;
Polivy (TN)
Product
Formula
C6670H10317N1745O2087S40
Exact mass
149533.3646
Mol weight
149625.3253
Remark
Product: D10761<US>
Efficacy
Antineoplastic
  Disease
B-cell lymphoma [DS:H00001]
Comment
Antibody-drug conjugate
See Vedotin [DR:D09691]
Target
CD79B [HSA:974] [KO:K06507]
  Pathway
hsa04662  B cell receptor signaling pathway
Brite
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Polatuzumab Vedotin
    D10761  Polatuzumab vedotin (USAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD79B
     D10761  Polatuzumab vedotin (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10761
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10761
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10761
Other DBs
CAS: 1313206-42-6
PubChem: 295369351

» Japanese version   » Back

DBGET integrated database retrieval system